EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report

Camilla Lisanti iD, Serena Della Rossa iD, Emma Zottarelli, Riccardo Vida, Silvia Bolzonello, Lucia Da Ros iD, Adrian Zdjelar, Erika Cecchin iD, Tiziana Perin, Fabio Puglisi iD

Current Oncology · 2025

DOI: 10.3390/curroncol32110606 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2025. Verfasst von Camilla Lisanti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Chemical and Drug Induced Liver Injury, Immunoconjugates. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab deruxtecan (T-DXd) has demonstrated efficacy in HER2-positive and HER2-low breast cancer. Its main safety concern is interstitial lung disease, while clinically relevant hepatotoxicity is rarely reported. In our case report we describe a 49-year-old woman with HER2-positive advanced breast cancer that developed persistent grade 3 transaminase elevations after 2 cycles of T-DXd, refractory to corticosteroid treatment and requiring treatment discontinuation. This case underlines the unpredictable and idiosyncratic nature of T-DXd associated hepatotoxicity and the importance of liver function monitoring. Clinicians should consider DILI in patients with unexplained liver enzyme elevations during therapy. Further studies are needed to clarify mechanisms and risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabBreast NeoplasmsChemical and Drug Induced Liver InjuryImmunoconjugatesCamptothecinAntineoplastic Agents, ImmunologicalHumansFemaleMiddle Aged

Stichwörter der Autor:innen

HER2-positive breast cancerdrug-induced liver injuryhepatotoxicitytrastuzumab deruxtecan

Substanzen

Trastuzumabtrastuzumab deruxtecanImmunoconjugatesCamptothecinAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
  • Department of Medicine (DMED), University of Udine, 33100 Udine, Italy.
  • Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
  • Department of Oncologic Radiation Therapy and Diagnostic Imaging, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
  • Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

ORCID-Profile: Camilla Lisanti, Serena Della Rossa, Lucia Da Ros, Erika Cecchin, Fabio Puglisi

Förderung

  • Italian Ministry of Health

Zitieren

APA

Lisanti, C., Della Rossa, S., Zottarelli, E., Vida, R., Bolzonello, S., Da Ros, L., Zdjelar, A., Cecchin, E., Perin, T., & Puglisi, F. (2025). Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report. Current Oncology. https://doi.org/10.3390/curroncol32110606

Vancouver

Lisanti C, Della Rossa S, Zottarelli E, Vida R, Bolzonello S, Da Ros L, et al. Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report. Current Oncology. 2025. doi:10.3390/curroncol32110606

BibTeX
@article{Lisanti2025,
  author = {Lisanti, Camilla and Della Rossa, Serena and Zottarelli, Emma and Vida, Riccardo and Bolzonello, Silvia and Da Ros, Lucia and Zdjelar, Adrian and Cecchin, Erika and Perin, Tiziana and Puglisi, Fabio},
  title = {Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32110606}
}
Kostenlos starten →